Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study

Milan J. Sonneveld,Fatemeh Parouei,Caroline den Hoed,Jeroen de Jonge,Morteza Salarzaei,Robert J. Porte,Harry L. A. Janssen,Marieke de Rosner‐van Rosmalen,Serge Vogelaar,Adriaan J. van der Meer,Raoel Maan,Sarwa Darwish Murad,Wojciech G. Polak,Willem Pieter Brouwer
DOI: https://doi.org/10.1111/ctr.15437
2024-08-24
Clinical Transplantation
Abstract:Background and Aims Biopsy‐proven severe graft steatosis is associated with adverse outcomes after liver transplantation. The concomitant presence of metabolic risk factors might further increase this risk. We studied the association between graft steatosis and metabolic risk factors in the donor, with recipient outcomes after liver transplantation. Methods We analyzed data from all consecutive first adult full‐graft donation after brain death (DBD) liver transplantations performed in the Eurotransplant region between 2010 and 2020. The presence of graft steatosis and metabolic risk factors was assessed through a review of donor (imaging) reports, and associations with recipient retransplantation‐free survival were studied through survival analyses. Results Of 12 174 transplantations, graft steatosis was detected in 2689 (22.1%), and donor diabetes mellitus (DM), hypertension, and dyslipidemia were present in 1245 (10.2%), 5056 (41.5%), and 524 (4.3%). In multivariable Cox regression analysis, graft steatosis (adjusted HR [aHR] 1.197, p
surgery,transplantation
What problem does this paper attempt to address?